PROCEPT BioRobotics Faces Class Action Over Inventory Practices

The legal action, spearheaded by Hagens Berman Sobol Shapiro LLP, centers on claims that PROCEPT misled shareholders by utilizing late-quarter discount programs to push excess inventory onto customers. These practices allegedly created a false impression of robust growth for the company's Aquablation therapy handpieces, while effectively cannibalizing future demand. By the time the company disclosed that it had accumulated over 10,000 units of excess customer inventory, the share price had plummeted more than 48% from its August 2025 peak.

Reed Kathrein, a partner at Hagens Berman, noted that the investigation is focused on whether management intentionally pulled sales forward to meet market expectations. The company only began to reveal the scope of the issue during quarterly earnings calls, culminating in the February 2026 admission that U.S. handpiece sales had consistently outpaced actual clinical procedures. The firm has set a lead plaintiff deadline of September 22, 2026, for investors seeking to participate in the recovery effort.